Peptide-Drug Conjugates: Targeted Cancer Delivery Including New PROTAC-Based Approaches
PDCs use tumor-homing peptides to deliver cytotoxic payloads directly to cancer cells, with emerging PROTAC-PDCs adding targeted protein degradation as a novel mechanism.
Quick Facts
What This Study Found
PDCs enable targeted delivery of cytotoxic payloads via tumor-homing peptides, with PROTAC-based PDCs emerging as a novel approach combining targeted delivery with targeted protein degradation.
Key Numbers
How They Did This
Narrative review of PDC design principles, components (tumor-homing peptides, linkers, payloads), recent anticancer applications, and emerging PROTAC-PDC technology.
Why This Research Matters
PDCs offer a simpler, cheaper alternative to antibody-drug conjugates (ADCs) for targeted cancer therapy, and the addition of PROTAC technology could enable unprecedented precision in cancer treatment.
The Bigger Picture
PDCs represent a convergence of peptide science, chemical biology, and oncology that could democratize targeted cancer therapy by making it simpler and more affordable than antibody-based approaches.
What This Study Doesn't Tell Us
Most PDCs are in preclinical development. In vivo stability and pharmacokinetics remain challenging. Clinical data is limited. Manufacturing scale-up for complex conjugates is non-trivial.
Questions This Raises
- ?Which PDC design features best predict clinical success?
- ?Can PROTAC-PDCs overcome resistance mechanisms that limit conventional PDCs?
- ?How do PDCs compare to ADCs in head-to-head studies?
Trust & Context
- Key Stat:
- PROTAC-PDC fusion Combining tumor-homing peptides with targeted protein degradation technology represents a new frontier in precision oncology
- Evidence Grade:
- Comprehensive review of a rapidly evolving field. Covers established principles and emerging technologies with primarily preclinical evidence.
- Study Age:
- Published in 2025.
- Original Title:
- Recent advances in peptide-drug conjugates as anticancer agents.
- Published In:
- European journal of medicinal chemistry, 304, 118482 (2026)
- Authors:
- Feng, Yanyan, Li, Tong, Li, Shijia, Liu, Zhouyan, Tang, Ziwei, Chen, Cheng, Zhou, Chen, Lu, Tulin, Chen, Jichao
- Database ID:
- RPEP-15162
Evidence Hierarchy
Frequently Asked Questions
What is a peptide-drug conjugate?
A PDC attaches a cancer-killing drug to a small peptide that can find and bind to cancer cells. The peptide acts like a GPS, guiding the drug directly to the tumor and away from healthy tissue.
How is this different from antibody-drug conjugates?
Both target drugs to tumors, but PDCs use smaller, simpler peptides instead of large antibodies. This makes them easier and cheaper to manufacture while still delivering drugs precisely to cancer cells.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15162APA
Feng, Yanyan; Li, Tong; Li, Shijia; Liu, Zhouyan; Tang, Ziwei; Chen, Cheng; Zhou, Chen; Lu, Tulin; Chen, Jichao. (2026). Recent advances in peptide-drug conjugates as anticancer agents.. European journal of medicinal chemistry, 304, 118482. https://doi.org/10.1016/j.ejmech.2025.118482
MLA
Feng, Yanyan, et al. "Recent advances in peptide-drug conjugates as anticancer agents.." European journal of medicinal chemistry, 2026. https://doi.org/10.1016/j.ejmech.2025.118482
RethinkPeptides
RethinkPeptides Research Database. "Recent advances in peptide-drug conjugates as anticancer age..." RPEP-15162. Retrieved from https://rethinkpeptides.com/research/feng-2026-recent-advances-in-peptidedrug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.